Amino acids in schizophrenia: Evidence for lower tryptophan availability during treatment with atypical antipsychotics?

Journal of Neural Transmission

Volumn 112, Issue 4, 2005, Pages 577-585

  Van Der Heijden, F M M A ^a   Fekkes, D ^b   Tuinier, S ^a   Sijben, A E S ^a   Kahn, R S ^c   Verhoeven, W M A ^a,b  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amino acids; Atypical antipsychotics; Schizophrenia; Serotonin

Indexed keywords

ALANINE; AMINO ACID; ATYPICAL ANTIPSYCHOTIC AGENT; GLUTAMIC ACID; GLYCINE; ISOLEUCINE; LEUCINE; METHIONINE; OLANZAPINE; PHENYLALANINE; QUETIAPINE; RISPERIDONE; SERINE; SERTINDOLE; TAURINE; TRYPTOPHAN; TYROSINE; VALINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SCHIZOPHRENIA;

ADULT; AMINO ACIDS, NEUTRAL; ANTIPSYCHOTIC AGENTS; BRAIN; DOWN-REGULATION; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEROTONIN; TRYPTOPHAN;

EID: 17644427329     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0200-5     Document Type: Article

References (43)

1. Bjerkensted L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA (1985) Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 147: 276-282
2. Carl GF, Brogan MP, Young BK (1992) Is plasma serine a marker for psychosis? Biol Psychiatry 31: 1130-1135
3. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41: 237-260
4. Curzon G (1990) Availability of amino acids to the brain and implication for transmitter amine function. In: Richardson MA (ed) Amino acids in psychiatric disease. American Psychiatric Press, Washington DC, pp 33-48
5. Dall'Olio R, Gandolfi O, Gaggi R (2002) D-Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behav Pharmacol 11: 631-637
6. Doorakkers MC, Verhoeven WMA, Tuinier S, van den Berg YWMM, Fekkes D, Pepplinkhuizen L (2001) Psychopathology, serotonergic parameters and sertindole; results of a preliminary study in schizophrenia. New Trends Exp Clin Psychiatry 17: 25-30
7. Evins AE, Amico ET, Shih V, Goff DC (1997) Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 104: 761-766
8. Faustman WO, Bardgett M, Faull KF, Pfefferbaum A, Csernansky JG (1999) Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 45: 68-75
9. Fekkes D, Pepplinkhuizen L (1997) Amino acid studies in transient acute polymorphic psychosis. Amino Acids 12: 107-117
10. Fekkes D, Pepplinkhuizen L, Verheij R, Bruinvels J (1994) Abnormal plasma levels of serine, methionine, and taurine in transient acute polymorphic psychosis. Psychiatry Res 51: 11-18
11. Fekkes D, van Dalen A, Edelman M, Voskuilen A (1995) Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phthaldialdehyde. J Chromatogr B Biomed Appl 669: 177-186
12. Fernstrom D, Wurtman RJ (1972) Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 178: 414-416
13. Gijsman HJ, Scarna A, Harmer CJ, McTavish SFB, Odontiadis J, Cowen PJ, Goodwin GM (2002) A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacol 160: 192-197
14. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377
15. Goff DC, Hennen J, Kyoon Lyoo I, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF (2002) Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51: 493-497
16. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of D-serine in patients with schizophrenia. Arch Gen Psychiatry 60: 572-576
17. van der Heijden FMMA, Verhoeven WMA, Fekkes D, Sijben AES, Tuinier S (2003) Quetiapine in relapsing schizophrenia: clinical efficacy and effect on monoaminergic parameters. Acta Neuropsychiatr 15: 133-139
18. van der Heijden FMMA, Tuinier S, Fekkes D, Sijben AES, Kahn RS, Verhoeven WMA (2004) Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 14: 259-265
19. Hong CJ, Tsai SJ, Wang YC (2001) Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders. Schizophr Res 49: 59-63
20. Lovenberg W, Jequier E, Sjoerdsma A (1968) Trypthophan hydroxylation in mammalian systems. Adv Pharmacol 6: 21-36
21. Lucca A, Lucini V, Catalano M, Smeraldi E (1995) Neutral amino acid availability in two major psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 19: 615-626
22. Macciardi F, Lucca A, Catalano M, Marino C, Smeraldi E (1990) Amino acid pattern in schizophrenia: some new findings. Psychiatry Res 32: 63-68
23. Markus CR, Olivier B, de Haan EHF (2002) Whey protein rich a-lactalbumin increases the ratio of plasma tryptophan to the sum of the large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr 75: 1051-1056
24. van der Mast RC, van den Broek WW, Fekkes D, Pepplinkhuizen L, Habbema JDF (2000) Is delirium after cardiac surgery related to plasma amino acids and physical condition? J Neuropsychiatry Clin Neurosci 12: 57-63
25. Mattson MP, Shea ThB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26: 137-146
26. Mooren R, Verhoeven WMA, Tuinier S, van den Berg YWMM, Fekkes D, Pepplinkhuizen L (2001) Olanzapine in relapsing schizophrenia. Efficacy and serotonergic parameters. Eur J Psychiatry 15: 91-100
27. Osmond H, Smythies J (1952) Schizophrenia; a new approach. J Ment Sci 98: 309-320
28. Pepplinkhuizen L, van der Heijden FMMA, Tuinier S, Verhoeven WMA, Fekkes D (2003) The acute transient polymorphic psychosis: a biochemical subtype of the cycloid psychosis. Acta Neuropsychiatr 15: 38-43
29. Rao ML, Gross G, Strebel B, Bräunig P, Huber G, Klosterkötter J (1990) Serum amino acids, central monoamines, and hormones in drug-naïve, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 34: 243-257
30. Reznik I, Sirota P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20: 410-416
31. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psych 50: 521-530
32. Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM (1997) Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiol 35: 5-10
33. Smythies JR, Gottfries CG, Regland B (1997) Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biol Psychiatry 41: 230-233
34. Stone TW (2001) Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Invest Drugs 10: 633-645
35. Sumiyoshi T, Elif Anil A, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropharmacol 7: 1-8
36. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M (2001) Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiol 44: 167-171
37. Verhoeven WMA, Rijn-Van den Meijdenberg JCC, Hofma E, Tuinier S, Fekkes D, Pepplinkhuizen L (1997) Amino acids, norharman and serotonergic parameters in schizophrenia: clinical and biochemical effects of treatment with risperidone. New Trends Exp Clin Psychiatry 13: 117-126
38. Waziri R, Mott J (1986) Drug effects on serine metabolism in psychiatric patients. Psychiatry Res 18: 119-126
39. Waziri R, Wilson R, Sherman AD (1983) Plasma serine to cysteine ratio as a biological marker for psychosis. Br J Psychiatry 143: 69
40. Waziri R, Wilcox J, Sherman AD, Mott J (1984) Serine metabolism and psychosis. Psychiatry Res 12: 121-136
41. Wurtman RJ, Hefti F, Melamed E (1981) Precursor control of neurotransmitter synthesis. Pharmacol Rev 32: 315-335
42. Wurtman RJ, Wurtman JJ, Regan MM, McDermott JM, Tsay RH, Breu JJ (2003) Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan an tyrosine ratios. Am J Clin Nutr 77: 128-132
43. Zullino D, Delacrausaz P, Baumann P (2002) The place of SSRIs in the treatment of schizophrenia. Encéphale 28: 433-438